AGLink® ADC Conjugation Kit (MMAE, DAR2&4, 1mg)

Antibody-drug conjugates (ADC) is a type of fast growing anticancer drug. Monoclonal antibody is conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity. AGLink® ADC conjugation kit is designed to conjugate mAb with toxic payload (MMAE) though site-specific enzymatic reaction.

AGLink® ADC Conjugation Kit (MMAE, DAR2&4, 1mg) is designed to conjugate 1mg mAb with toxic payload (MMAE) through site-specific enzymatic reaction.

It is for research use only.

• Site-specific conjugation through Fc-glycan with high conjugation efficiency
• Uniform DAR value and highly homogeneous ADC products
• No need of amino acid sequence engineering
• Easy to use: One-pot & One-step
• Two options: DAR2 & DAR4 ADC product

BoxA: The unopened kit is stable for 18 months from the date of manufacture if stored under temperature ≤ -20°C. The opened kit should be stored according to components table.

BoxB: The unopened kit is stable for 18 months from the date of manufacture if stored under 4°C. The opened kit should be stored according to components table.